Endocannabinoid: Difference between revisions
Jump to navigation
Jump to search
imported>Richard Pettitt (Endocannabinoid moved to Endocannabinoid system in appetite regulation: This article is great, but misnamed.) |
imported>Richard Pettitt No edit summary |
||
| Line 1: | Line 1: | ||
# | {{subpages}} | ||
An '''endocannabinoid''' ('''endo'''genous '''cannabinoid''') is a neurotransmitter created in the brain which binds to cannabinoid receptors. | |||
== The Endocannabinoids == | |||
#Anandamide<ref name="pmid1470919">{{cite journal |author=Devane WA, Hanus L, Breuer A, ''et al'' |title=Isolation and structure of a brain constituent that binds to the cannabinoid receptor |journal=Science |volume=258 |issue=5090 |pages=1946–9 |year=1992 |pmid=1470919}}</ref> | |||
#2-Arachidonoylglycerol (2-AG)<ref name="pmid9285589">{{cite journal |author=Stella N, Schweitzer P, Piomelli D |title=A second endogenous cannabinoid that modulates long-term potentiation |journal=Nature |volume=388 |issue=6644 |pages=773–8 |year=1997 |pmid=9285589}}</ref> | |||
#2-arachidonyl glyceryl ether<ref name="pmid11259648">{{cite journal |author=Hanus L, Abu-Lafi S, Fride E, ''et al'' |title=2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=98 |issue=7 |pages=3662–5 |year=2001 |pmid=11259648}}</ref> | |||
#N-arachidonoyl-dopamine (NADA)<ref name="pmid16760924">{{cite journal |author=Marinelli S, Di Marzo V, Florenzano F, ''et al'' |title=N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors |journal=Neuropsychopharmacology |volume=32 |issue=2 |pages=298–308 |year=2007 |pmid=16760924}}</ref> | |||
#Virodhamine<ref name="pmid12023533">{{cite journal |author=Porter AC, Sauer JM, Knierman MD, ''et al'' |title=Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor |journal=J. Pharmacol. Exp. Ther. |volume=301 |issue=3 |pages=1020–4 |year=2002 |pmid=12023533}}</ref> | |||
== Role in appetite == | |||
{{Main|Endocannabinoid system in appetite regulation}} | |||
Smoking cannabis is a potent stimulator of appetite, and is sometimes prescribed for medicinal purposes to stimulate eating. The role of the endocannabinoid system in appetite regulation has been investigated through the discovery of a CB1 selective antagonist. Antagonism of the CB1 receptor has significant appetite reducing and weight reduction effects. This factor, coupled to the appetite enhancing affects of anandamide and THC and because the CB1 receptor and endocannabinoids are expressed in brain regions associated with appetite regulation, provided the impetus for the drive in research centered around how the EC system is implicated in appetite regulation. | |||
== References == | |||
<references/> | |||
Revision as of 01:18, 18 December 2007
An endocannabinoid (endogenous cannabinoid) is a neurotransmitter created in the brain which binds to cannabinoid receptors.
The Endocannabinoids
- Anandamide[1]
- 2-Arachidonoylglycerol (2-AG)[2]
- 2-arachidonyl glyceryl ether[3]
- N-arachidonoyl-dopamine (NADA)[4]
- Virodhamine[5]
Role in appetite
Smoking cannabis is a potent stimulator of appetite, and is sometimes prescribed for medicinal purposes to stimulate eating. The role of the endocannabinoid system in appetite regulation has been investigated through the discovery of a CB1 selective antagonist. Antagonism of the CB1 receptor has significant appetite reducing and weight reduction effects. This factor, coupled to the appetite enhancing affects of anandamide and THC and because the CB1 receptor and endocannabinoids are expressed in brain regions associated with appetite regulation, provided the impetus for the drive in research centered around how the EC system is implicated in appetite regulation.
References
- ↑ Devane WA, Hanus L, Breuer A, et al (1992). "Isolation and structure of a brain constituent that binds to the cannabinoid receptor". Science 258 (5090): 1946–9. PMID 1470919.
- ↑ Stella N, Schweitzer P, Piomelli D (1997). "A second endogenous cannabinoid that modulates long-term potentiation". Nature 388 (6644): 773–8. PMID 9285589.
- ↑ Hanus L, Abu-Lafi S, Fride E, et al (2001). "2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor". Proc. Natl. Acad. Sci. U.S.A. 98 (7): 3662–5. PMID 11259648.
- ↑ Marinelli S, Di Marzo V, Florenzano F, et al (2007). "N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors". Neuropsychopharmacology 32 (2): 298–308. PMID 16760924.
- ↑ Porter AC, Sauer JM, Knierman MD, et al (2002). "Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor". J. Pharmacol. Exp. Ther. 301 (3): 1020–4. PMID 12023533.